Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIFEN: Fenofibrate in Newly Diagnosed Type 1 Diabetes
NCT05909800Phase 2Unknown
- Sponsor
- Medical University of Warsaw
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Phenofibrate with Placebo (2 arms). Primary endpoint: Area Under the Curve of C-peptide in stimulation test at 12 months. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05909800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909800.